FDA OKs Cabozantinib for Pancreatic Neuroendocrine Tumors

Cabometyx wins FDA approval to treat certain pancreatic cancers

The U.S. Food and Drug Administration (FDA) has granted its approval to the oral medication Cabometyx (cabozantinib) as a treatment for certain types of pancreatic cancer. The approval specifically covers the use of Cabometyx for patients ages 12 and older who have previously treated, unresectable — meaning the cancer cannot be surgically removed — locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors. The therapy …

Curcumin Ameliorates Cerulein‑Induced Chronic Pancreatitis through Nrf‑2/HO‑1 Signaling

Researchers investigated whether curcumin improved cerulein‑induced chronic pancreatitis fibrosis in a mouse model and pancreatic stellate cells. [Molecular Medicine Reports] Abstract

FDA OKs Cabozantinib for Pancreatic Neuroendocrine Tumors

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo. Medscape Medical News

Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors

The FDA has approved Exelixis' cancer drug Cabometyx to treat advanced neuroendocrine tumors inside and outside of the pancreas, marking two new indications for the company’s primary source of revenue. The new label includes adults ...

#Exelixis Secures FDA Approval for CABOMETYX A Step Forward for Neuroendocrine Tumor Treatment Amid Market Dynamics

In a significant advancement in cancer treatment, Exelixis, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX (cabozantinib) for patients aged 12 years and older with previously treated advanced neuroendocrine tumors (NET). This approval marks a notable milestone in the management of well-differentiated pancreatic neuroendocrine tumors (pNET), as it provides new hope for patients with unresectable, locall…

FDA Approves Cabometyx to Treat Advanced Pancreatic Cancer

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.